We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Biocon, Mylan in pan-biogenerics deal.
- Authors
Jayaraman, Killugudi
- Abstract
The article reports on the partnership between Bangalore, India-based Biocon and U.S.-based Mylan to sell Indian-made biogenerics globally. The partnership involves the selling of generic versions of insulin, monoclonal antibodies and other protein therapeutics to regulated markets such as the U.S. and Europe. Under their agreement, the two firms will share development, capital and certain other costs of bringing the products into global markets.
- Subjects
UNITED States; EUROPE; BUSINESS partnerships; BIOCON Inc.; MYLAN NV; INSULIN therapy; THERAPEUTIC use of monoclonal antibodies
- Publication
Nature Biotechnology, 2009, Vol 27, Issue 9, p786
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0909-786b